A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma

Overview of attention for article published in American Journal of Hematology, June 2013

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 X post from an account with 968 followers.

A phase I trial of CpG 7909 & 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed Bcell-NHL http://t.co/ceS801rB7n

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.